SCHEMBL7218671

SCHEMBL7218671

O=C(O)C=C(c1ccccc1)c1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
SMO Q99835 1/20 0.47
POLB P06746 2/20 0.46
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
SLC6A1 P30531 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937427 0.85 KMT2A (0.64) ALDH1A1CES2CES1POLBHPGD
SCHEMBL8937417 0.85 KMT2A (0.64) ALDH1A1CES2CES1POLBHPGD
SCHEMBL8937423 0.85 KMT2A (0.64) ALDH1A1CES2CES1POLBHPGD
SCHEMBL8937293 0.81 KMT2A (0.56) ALDH1A1CES2CES1NPC1RAB9A
SCHEMBL8937295 0.81 KMT2A (0.56) ALDH1A1CES2CES1NPC1RAB9A
SCHEMBL8937298 0.81 KMT2A (0.56) ALDH1A1CES2CES1NPC1RAB9A
SCHEMBL63954 0.80 CES1 (0.50) ALDH1A1CES2CES1POLBHPGD
SCHEMBL14200705 0.79 ALDH1A1 (0.48) ALDH1A1CES2CES1SMOPOLB
Hydrochloric Acid SCHEMBL4398755 0.78 NFE2L2 (0.48) ALDH1A1CES2CES1POLBHPGD
SCHEMBL7820881 0.77 ALDH1A1 (0.57) ALDH1A1CES2CES1SMOPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624197-B1 Styrene administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulinemic and CALYX THERAPEUTICS, INC. 2003-09-23 US disclosed